Hitoshi Sase - Concepedia

Author

Hitoshi Sase

The University of Tokyo

Also Known As

Hitoshi Sase

Publications

474

Citations

H-Index

Concepts

All Affiliations

The University of Tokyo Keio University

About

Hitoshi Sase is an author at The University of Tokyo specializing in cell biology, tumor microenvironment, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	220
2	Cell Biology	4	4	220
3	Health Sciences	2	2	76
4	Immunology	2	2	76
5	Pharmacology	2	2	144

Hitoshi Sase

Publications

465

Citations

H-Index

Page 1

	Year	Citations
Arkadia Induces Degradation of SnoN and c-Ski to Enhance Transforming Growth Factor-β Signaling Yoshiko Nagano, Konstantinos J. Mavrakis, Kian Leong Lee, Journal of Biological Chemistry	2007	161
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Molecular Cancer Therapeutics Radiation OncologyFgf ReceptorsNovel TherapyFgfr EnzymesMedicine	2014	119
Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells Kyoko Kawasaki, Tetsuro Watabe, Hitoshi Sase, The Journal of Cell Biology	2008	46
VEGFR2-PLCγ1 axis is essential for endothelial specification of VEGFR2+ vascular progenitor cells Hitoshi Sase, Tetsuro Watabe, Kyoko Kawasaki, Journal of Cell Science ImmunologyTyrosine 1175Vegfr2-plcγ1 AxisAngiogenesisVegfr2-plcgamma1 Signal Relay	2009	43
Identification of targets of Prox1 during in vitro vascular differentiation from embryonic stem cells: functional roles of HoxD8 in lymphangiogenesis Kaori Harada, Tomoko Yamazaki, Caname Iwata, Journal of Cell Science ImmunologyLymphatic Endothelial CellsProx1 ExpressionFunctional RolesCell Specialization	2009	33
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor Yoshito Nakanishi, Hideaki Mizuno, Hitoshi Sase, Molecular Cancer Therapeutics Erk Signal SuppressionCancer BiologyTumor BiologySignaling PathwayReceptor Tyrosine Kinase	2015	25
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer Hiroshi Tanaka, Hitoshi Sase, Toshiyuki Tsukaguchi, Molecular Cancer Therapeutics	2018	20
Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in <i>FGFR2</i> -Amplified Gastric Cancer Hitoshi Sase, Yoshito Nakanishi, Satoshi Aida, Molecular Cancer Therapeutics	2018	18

Page 1